Business
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in year one) triggered GENFIT’s €17.0 million ($20.0 million) milestone, included in reported revenues, but not yet reflected in the cash positionACLF and CCA programs progressing according to plan Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 26, 2026 - GENFIT
About this update from Genfit Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Cash and cash equivalents totaled €101.1 million as of December 31, 2025","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenues amounted to €65.4 million as of December 31, 2025","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in year one) triggered GENFIT’s €17.0 million ($20.0 million) milestone, included in reported revenues, but not yet reflected in the cash position","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"ACLF and CCA programs progressing according to plan","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":395,"olType":false},{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 26, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its fourth quarter 2025 revenues and cash position results1 and provides a corporate update.","length":353,"tagName":"p"},{"type":"text","content":"I. Cash position","length":16,"tagName":"p"},{"type":"text","content":"As of December 31, 2025, the Company’s cash and cash equivalents amounted to €101.1 million compared with €81.8 million as of December 31, 2024 and €119.0 million as of September 30, 2025.","length":188,"tagName":"p"},{"type":"text","content":"In 2025, cash utilization is mainly the result of our research and development efforts in our Acute on-Chronic Liver Failure (ACLF) franchise (notably VS-01, NTZ/G1090N, SRT-015, CLM-022, and VS-02 HE), as well as GNS561 in cholangiocarcinoma (CCA). Cash utilization is offset notably by the €26.55 million milestone received in July 2025 (invoiced in May 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in Italy, the third major European country to do so, as part of our long-term strategic partnership with Ipsen (the “Ipsen Agreement”) signed in December 2021.","length":586,"tagName":"p"},{"type":"text","content":"In January 2026, GENFIT exercised its option to receive (and did in fact receive) the second installment of the Royalty Financing agreement totaling €30.0 million. Both this amount, as well as the first commercial milestone of €17.0 million ($20.0 million) th...